Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, PA, USA.
Immunotherapy. 2012 Aug;4(8):761-72. doi: 10.2217/imt.12.70.
Led by key opinion leaders in the field, the Cancer Immunotherapy Consortium of the Cancer Research Institute 2012 Scientific Colloquium included 179 participants who exchanged cutting-edge information on basic, clinical and translational cancer immunology and immunotherapy. The meeting revealed how rapidly this field is advancing. The keynote talk was given by Wolf H Fridman and it described the microenvironment of primary and metastatic human tumors. Participants interacted through oral presentations and panel discussions on topics that included host reactions in tumors, advances in imaging, monitoring therapeutic immune modulation, the benefit and risk of immunotherapy, and immune monitoring activities. In summary, the annual meeting gathered clinicians and scientists from academia, industry and regulatory agencies from around the globe to interact and exchange important scientific advances related to tumor immunobiology and cancer immunotherapy.
由该领域的主要意见领袖领导,癌症研究学会癌症免疫治疗联盟 2012 年科学座谈会包括 179 名参与者,他们交流了癌症免疫和免疫治疗的基础、临床和转化方面的最新信息。会议揭示了这个领域的发展速度有多快。Wolf H Fridman 作了主题演讲,描述了原发性和转移性人类肿瘤的微环境。参与者通过口头报告和小组讨论进行互动,讨论的主题包括肿瘤中的宿主反应、成像技术的进展、治疗性免疫调节的监测、免疫治疗的益处和风险,以及免疫监测活动。总之,年会汇集了来自全球学术界、工业界和监管机构的临床医生和科学家,他们互动交流与肿瘤免疫生物学和癌症免疫治疗相关的重要科学进展。